Exhibit 99.1


Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update


Staten Island, NY, November 12, 2021 — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the quarter ended September 30, 2021.


Highlights of, and certain events subsequent to, the third quarter of 2021 include:


·12 clinical trial sites have been activated to commence enrollment of the Company’s Phase 2b clinical trial of patients with C difficile infection (CDI) with enrollment expected to be completed in the third quarter of 2022;
·Additional microbiome data from the Phase 2a trial of ibezapolstat in patients with CDI were presented at two prominent scientific conferences shortly after completion of the third quarter;
·This Ph2a trial demonstrated 100% clinical cure and 100% sustained clinical cure with ibezapolstat along with beneficial microbiome changes during treatment including overgrowth of Actinobacteria and Firmicutes phylum species while on therapy and new findings which demonstrate potentially beneficial effects on bile acid metabolism
·These reported clinical results support the expectation that microbiome effects may be predictive of beneficial patient outcomes including low rates of recurrence
·The previously announced R&D program in collaboration with Leiden University Medical Center in Holland was launched to further evaluate the mechanism-of-action of Acurx’s inhibitors against the DNA pol IIIC enzyme, which is the bacterial target of our antibiotic product pipeline.


Third Quarter 2021 Financial Results


Research and development expenses for the three months ended September 30, 2021 were $1.1 million compared to $0.7 million for the three months ended September 30, 2020. The increase is primarily due to Phase 2B trial related costs. For the nine-months ended September 30, 2021, research and development expenses were $1.3 million compared to $1.7 million for the nine-months ended September 30, 2020. The decrease is due to the Phase 2a trial related costs which was completed in 2020.


Selling, general and administrative expenses for the three months ended September 30, 2021 were $3.5 million compared to $0.7 million for the three months ended September 30, 2020.   The increase was primarily due to non-cash stock-based compensation and increases in professional fees, insurance and legal costs.


For the nine-months ended September 30, 2021, selling, general and administrative expenses were $8.9  million compared to $1.8 million for the nine-months ended September 30, 2020. The increase in general and administrative expenses is primarily attributable to increases in non-cash stock-based compensation, professional fees, stock-based director fees, and insurance and legal costs.




The Company reported a net loss of $4.6 million or $(0.46) per diluted share for the three months ended September 30, 2021 compared to a net loss of $1.3 million or $(0.21) per diluted share for the three months ended September 30, 2020 and a net loss of $10.1 million or $(1.27) per diluted share for the nine-months ended September 30, 2021, compared to a net loss of $3.5 million or $(0.58) per diluted share for the nine-months ended September 30, 2020, for the reasons previously mentioned.


As of September 30, 2021, the Company had a cash balance of $14.5 million.


Conference Call


As previously announced, David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:


Date:    Monday, November 15, 2021
Time:    8:30 a.m. ET
Toll free (U.S. and International):   877-790-1503
Conference ID: 13724324


About Ibezapolstat


Ibezapolstat is a novel, orally-administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS™) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome.


In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted “Fast Track” designation to ibezapolstat for the treatment of patients with CDI.


The Company successfully completed Phase 1 and Phase 2a clinical trials of ibezapolstat and in the second half of 2021 it expects to begin enrollment of its Phase 2b vancomycin-controlled efficacy study in a 1:1 randomized trial of a total of 64 patients with CDI.


The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI.


About Acurx Pharmaceuticals, Inc.


Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).


To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.




Forward-Looking Statements


Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other factors. In addition, the forward-looking statements included in this press release represent our views as of November 12, 2021. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward- looking statements at some point in the future, we specifically disclaim any obligation to do so.


Investor Contact:


Acurx Pharmaceuticals, Inc.

David P. Luci, President & Chief Executive Officer

Tel: 917-533-1469

Email: davidluci@acurxpharma.com










   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
OPERATING EXPENSES                    
Research and Development  $1,126,972   $659,977   $1,313,954   $1,745,446 
General and Administrative   3,515,250    654,569    8,873,160    1,761,561 
TOTAL OPERATING EXPENSES   4,642,222    1,314,546    10,187,114    3,507,007 
Gain on forgiveness of Paycheck Protection Program Loan           66,503     
NET LOSS  $(4,642,222)  $(1,314,546)  $(10,120,611)  $(3,507,007)
LOSS PER SHARE                    
Basic and diluted net loss per common share/units  $(0.46)  $(0.21)  $(1.27)  $(0.58)
Weighted average pro forma shares outstanding basic and diluted   10,116,403    6,266,584    7,988,563    6,037,254 








   September 30,   December 31, 
   2021   2020 
Cash  $14,459,046   $3,175,411 
Prepaid Expenses   530,582    48,609 
TOTAL ASSETS  $14,989,628   $3,224,020 
Accounts Payable and Accrued Expenses  $712,437   $455,931 
Paycheck Protection Program Loan       16,625 
TOTAL CURRENT LIABILITIES   712,437    472,556 
Paycheck Protection Program Loan       49,878 
TOTAL LIABILITIES   712,437    522,434 
Members' Equity, Class A       16,402,198 
Members' Equity, Class B       100,000 
Common Stock; $.001 par value, 200,000,000 shares authorized, 10,126,903 shares issued and outstanding at September 30, 2021   10,127     
Additional Paid-In capital   38,188,287     
Accumulated Deficit   (23,921,223)   (13,800,612)
TOTAL MEMBERS' AND SHAREHOLDERS' EQUITY   14,277,191    2,701,586